FHFlorian Hentschel

Florian Hentschel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florian Hentschel has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oxidants, antioxidants, and the clinical course of COVID-19 disease: a prospective observational study

    by Werner Dammermann, Wencke Schürmann, Till Bornscheuer, Stefan Lüth, Dominique Petrus, Sandra Schwarzlose-Schwarck, Florian Hentschel

    Background: Microvascular damage by oxidative stress is central in the pathogenesis of generalized COVID-19 disease. Hence, a disbalance of endothelial-derived oxidative and anti-oxidative factors in COVID-19 patients can be expected, and the extent of this disbalance might correlate with disease severity. Methods: We measured xanthine oxidase (XO), superoxide dismutase (SOD), catalase (CAT), and ischemia modified albumin (IMA) in serum samples of 166 COVID-19 patients and 238 controls. We then cathegorized the COVID-19 group further into mild, moderate, severe and lethal courses and tested these for correlation with each parameter alone, and with multi-parametric logistic regression analysis. Results: Compared to controls, XO was significantly lower in COVID-19 patients, SOD and CAT were significantly higher. Difference in IMA was insignificant. In the single parameter analysis, only CAT concentration was significantly correlated to disease severity. In the logistic regression analysis, XO and SOD were negatively correlated with disease severity. Conclusions: Oxidative stress in COVID-19 does derive from other sources than endothelial XO. The rise in protective enzymes like SOD and CAT may be the result of enzyme induction. Since the correlation of CAT with disease severity was highest, we propose this parameter as a possible predictor for a severe clinical course.

  • Open Access

    Food impactions in the esophagus: incidence, causes, and treatment

    by Florian Hentschel, Isabel Elena Haller, Juliane Emily Wruck, Benedikt Seckinger, Götz Mollenhauer, Till Bornscheuer, Stefan Lüth

    Food impactions in the esophagus are gastroenterologic emergencies. Their incidence is suspected to increase. Standard therapy is endoscopic removal. According to European guidelines from 2016, gently pushing the food forward with the endoscope is safe and efficient. This has recently been doubted, and a retrograde extraction of the food bolus was supposed to be safer. We retrospectively analyzed all food impactions in our database over 16 years regarding incidence per year, age, sex, underlying disease, method of removal, success rate, and safety. From 2008 to 2024, 99 patients were included. Incidence of food impactions increased logarithmically from one per year to 22 per year (p < 0.001). Seventy-nine patients were male (80%; p < 0.001). Underlying diseases were reflux-associated lesions, eosinophilic esophagitis, pseudo­diverticulosis, hernia, achalasia, candidiasis, and others. Fifty-five were pushed forward prior to 2016, afterwards it were 74 (56% and 75% respectively; p < 0.001). Success rate was 100 percent for all techniques. We observed two minor adverse events in the forward-pushing group vs. one in the extraction group (not significant). Our data confirms that food obstructions are on the rise and that the vast majority of patients are male. There is no typical underlying disease but a wide variety of rare diseases which together form the basis for the increase. Pushing forward is as safe as is extracting the food, so we see no necessity to change the existing guidelines.


  • Medium-term outcomes after magnetic sphincter augmentation vs. fundoplication for reflux disease due to hiatal hernia: a propensity-score matched comparison in 282 patients

    by Marius Jonathan Ibach, Paul Martin Dahlke, Simon Wiegrebe, Florian Hentschel, Björn Siemssen

    Background An increasing number of reflux patients opt for magnetic sphincter augmentation (MSA) instead of fundoplication. However, few studies compare the medium-term efficacy and safety of the procedures. Methods We conducted a retrospective single-center analysis of consecutive MSA and Nissen fundoplication cases between 01/2015 and 06/2020. Patients underwent surgery, including hiatoplasty, for medical treatment-resistant reflux due to hiatal hernia. Surgical revision and proton pump inhibitor (PPI) reuptake rates were the primary outcomes. We also compared adverse event rates. Patients with severe preoperative dysphagia/motility disorders were assigned different treatment pathways and excluded from the analysis. We used propensity-score matching to reduce confounding between treatments. Results Out of 411 eligible patients, 141 patients who underwent MSA and 141 with fundoplication had similar propensity scores and were analyzed. On average, patients were 55 ± 12 years old and overweight (BMI: 28 ± 5). At 3.9 years of mean follow-up, MSA was associated with lower surgical revision risk as compared to fundoplication (1.2% vs 3.0% per year, respectively; HR: 0.38; 95% CI 0.15–0.96; p = 0.04), and similar PPI-reuptake risk (2.6% vs 4.2% per year; HR: 0.59; 95% CI 0.30–1.16; p = 0.12). Adverse event rates during primary stay were similar (MSA vs. fundoplication: 1% vs. 3%, p = 0.68). Fewer patients experienced adverse events in the MSA group after discharge (24% vs. 33%, p = 0.11), driven by higher rates of self-limiting dysphagia (1% vs. 9%, p < 0.01) and gas/bloating (10% vs. 18%, p = 0.06) after fundoplication. Differences between MSA and fundoplication in dysphagia requiring diagnostic endoscopy (11% vs. 8%, p = 0.54) or surgical revision (2% vs. 1%, p = 1.0) were non-significant. The device explantation rate was 4% (5/141). Conclusion MSA reduces the re-operation risk compared to fundoplication and may decrease adverse event rates after discharge. Randomized head-to-head studies between available surgical options are needed. Graphical abstract


  • Long-term results after laparoscopic revision fundoplication: a retrospective, single-center analysis in 194 patients with recurrent hiatal hernia

    by Björn Siemssen, Florian Hentschel, Marius Jonathan Ibach

    Background After laparoscopic fundoplication, 10–20% of patients experience symptom recurrence—often due to resurgence of the hiatal hernia. The standard surgical treatment for such cases remains laparoscopic revision fundoplication. However, there is little data on the time frame and anatomic patterns of failed fundoplications. Additionally, few large studies exist on the long-term efficacy and safety of laparoscopic revision fundoplication. Methods In a single-center, retrospective analysis of 194 consecutive revision fundoplications for recurrent reflux disease due to hiatal hernia, we collected data on time to failure and patterns of failure of the primary operation, as well as on the efficacy and safety of the revision. Results The median time to failure of the primary fundoplication was 3 years. Most hiatal defects were smaller than 5 cm and located anteriorly or concentric around the esophagus. Laparoscopic redo fundoplication was technically successful in all cases. The short-term complication rate was 9%, mainly dysphagia requiring endoscopic intervention. At a mean follow-up of 4.7 years, 77% of patients were symptom-free, 14% required daily PPI, and 9% underwent secondary revision. Cumulative failure rates were 9%, 23%, and 31% at 1, 5, and 10 years. Conclusion The majority of failed fundoplications occur within 3 years of primary surgery, with most patients exhibiting anterior or concentric defects. For these patients, laparoscopic revision fundoplication is a safe procedure with a low rate of short-term complications and satisfactory long-term results.


  • Medium term (> 12 months) outcomes after laparoscopic hiatal hernia repair without conventional fundoplication using PH4B-mesh implant (Phasix™) in 176 reflux patients: experience and technique

    by B Siemssen, P M Dahlke, F Behrens, F Hentschel, M J Ibach

    Background Hiatal mesh repair remains a controversial topic among anti-reflux surgeons. Biosynthetic mesh cruroplasty may prevent early recurrence while avoiding late esophageal erosion and strictures associated with non-resorbable materials. So far, medium-term results on hiatal PH4B (Poly-4-Hydroxybutyrate) mesh repair from high-volume centers are lacking. Methods We analyzed the medium-term efficacy and safety of PH4B mesh cruroplasty in 176 consecutive patients (≥ 18 years) with symptomatic hiatal hernias. Treatment failure was defined as the clinical recurrence of reflux symptoms. Patients could choose between mesh augmented hiatal repair (combined with a modified anterior hemifundoplication and fundophrenicopexy), Nissen fundoplication, and magnetic sphincter augmentation at their discretion. We also describe the surgical approach to mesh augmented hiatal repair used at our center. Results On average, patients were 55 (± 14) years old and followed up for 22 (± 7; sum: 3931) months. Treatment failed in 6/176 (3%, 95% CI: 2–7%) patients. The 24-month Kaplan–Meier failure estimate was 2.8% (95% CI: 0.4–5%). Each centimeter in hernia size increased the risk of failure by 52% (p = 0.02). Heavier patients (BMI > 27) had an 11% higher probability of clinical symptom recurrence (p = 0.03). The dysphagia and bloating/gas rate were 13/176 (7%), each. 8 (5%) patients required endoscopy due to dysphagia but without intervention. No serious complications, including mesh infection and erosion, or fatalities, occurred. Conclusion Augmented PH4B mesh cruroplasty without conventional fundoplication shows excellent intermediate-term results in patients with reflux disease due to hiatal hernia. Around one in thirty patients experience treatment failure within 2 years of surgery. Hernia size and overweight are key determinants of treatment failure.


  • Open Access

    Placing vacuum sponges in esophageal anastomotic leaks — how we do it

    by Florian Hentschel, Götz Mollenhauer, Björn Siemssen, Christoph Paasch, René Mantke, Stefan Lüth

    Purpose: Endoluminal vacuum sponge therapy has dramatically improved the treatment of anastomotic leaks in esophageal surgery. However, the blind insertion of vacuum sponge kits like Eso-Sponge® via an overtube and a pusher can be technically difficult. Methods: We therefore insert our sponges under direct visual control by a nonstandard “piggyback” technique that was initially developed for the self-made sponge systems preceding these commercially available kits. Results: Using this technique, we inserted or changed 56 Eso-Sponges® in seven patients between 2018 and 2023. Apart from one secondary sponge dislocation, no intraprocedural complications were encountered. One patient died due to unrelated reasons. In all others, the defects healed and they were dismissed from the hospital. Long-term follow-up showed three strictures that were successfully treated by dilatation. Conclusion: We conclude that sponge placement via piggyback technique is a fast, safe, and successful alternative to the standard method of insertion.

  • Open Access

    Asymptomatic arbovirus and campylobacter infections in German travelers to Asia

    by Werner Dammermann, Isabel-Elena Haller, Katrin Singethan, Christof D. Vinnemeier, Florian Hentschel

    The true risk for many travel diseases is unknown because most studies do not detect asymptomatic infections. In this study, we performed ELISA for dengue virus (DENV), chikungunya virus (CHIKV), Zika virus (ZIKV), hepatitis E virus (HEV), and Campylobacter jejuni on samples from 81 healthy Germans before and after they traveled to Asia. ELISA found five seroconversions for C. jejuni, two for DENV, one for ZIKV, and zero for HEV. For CHIKV, three subjects were positive before travel and negative afterwards. None had symptoms. These infections would have gone unnoticed by retrospective studies. Therefore, the risk for these infections may be higher than previously estimated.

  • Open Access

    Asymptomatic Arbovirus, Campylobacter but no Hepatitis E Infections in German Travelers to Asia

    by Werner Dammermann, Isabel-Elena Haller, Katrin Singethan, Sven Pischke, Christof Vinnemeyer, Stefan Lüth, Florian Hentschel

    Purpose: Transmission of infectious travel diseases is increasing, especially in travelers from developed to developing countries. Still, the incidence of many travel diseases is not known, because retrospective surveillance systems do not detect asymptomatic infections. Methods: We took medical history and blood samples of 81 German travelers before and after travelling to South and Southeast Asia. IgG, IgM, and if possible IgA antibody titers were measured for Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV), Hepatitis E virus (HEV), and Camphylobacter jejuni (C.jejuni) using commercial ELISA kits. Additionally, we tested for Cytomegalovirus and Helicobacter pylori. Results: No symptoms were reported. Still, we found one anti-ZIKV and two anti-DENV IgG seroconversions. For CHIKV, we found three individuals who were IgG-positive before travel and negative afterwards. We found five IgG seroconversions for C.jejuni and zero for HEV. We also found one IgG seroconversion for CMV, and zero for H.pylori. Calculated incidences were between zero and 6.5%. Conclusion: Using serological analyses, we found a small but significant number of travel infections that would have gone unnoticed by retrospectively asking for symptoms alone. This suggests that the risk for these infections may be higher than previously estimated.

  • Open Access

    Psoas muscle index predicts time to rehospitalization in liver cirrhosis: An observational study

    by Florian Hentschel, Theresa Schwarz, Stefan Lüth, Andreas G. Schreyer

    Sarcopenia is frequent in liver cirrhosis (LC) where it is associated with morbidity and mortality. However, prognostic scores such as model for end-stage liver disease (MELD), MELD-sodium (MELD-Na), or Child–Turcotte–Pugh (CTP) do not contain sarcopenia as a variable. For this study, we utilized psoas muscle index (PMI) to objectively determine sarcopenia in hospitalized LC patients, and evaluated it as a predictor of time between discharge and readmission in LC. Abdominal computed tomography and magnetic resonance imaging scans of 65 consecutive LC patients were retrospectively examined to determine PMI. MELD, MELD-Na, and CTP were calculated from clinical data. PMI was then combined with CTP to form an experimental score: CTP sarcopenia (CTPS). For PMI alone and for each score, correlation with time between discharge and readmission for liver-related complications was calculated. PMI was also tested for correlation with sex, body mass index (BMI), MELD, MELD-Na, and CTP. CTPS was most closely correlated with time to readmission (R = 0.730; P < .001), followed by CTP (R = 0.696; P < .001), MELD-Na (R = 0.405; P = .009), and PMI alone (R = 0.388; P = .01). Correlation with MELD (R = 0.354; P = .05) was lowest. Additionally, there were significant differences in PMI between male and female individuals (5.16 vs 4.54 cm2/m2; P = .04) and in BMI between sarcopenic and nonsarcopenic individuals (29.63 vs 25.88 kg/m2; P = .009). Sarcopenia is an independent short-term prognostic factor in LC. By combining data on sarcopenia with CTP, we created an experimental score that predicts time to readmission better than MELD, MELD-Na, or CTP.


  • Open Access

    Insulin‐like growth factor 1 and dehydroepiandrosterone levels in alcoholic liver cirrhosis

    by Werner Dammermann, Benedikt Seckinger, David Füller, Stefan Lüth, Florian Hentschel

    Anabolic hormones in liver cirrhosis are suspected to be lower than in healthy individuals. In a group of 22 cirrhosis patients, we found lower levels of insulin‐like growth factor 1, but—surprisingly—higher levels of dehydroepiandrosterone.